Table 3.

Prevalence of recalling experiences from anaesthetic-induced unresponsiveness (Experiment 1) and non-rapid eye movement sleep (Experiment 2). ∗Differences were not observed in drug plasma concentrations measured immediately before the interview (UR1, UR2, and R3 states combined) between those who reported no recall or content reports in either dexmedetomidine (N=39, F(1, 19)=0.384, P=0.543; geometric mean ContentReport=1.54 ng ml⁻¹; geometric mean NoRecall=1.45 ng ml⁻¹) or propofol (N=29, F(1, 10)=0.589, P=0.460; geometric mean ContentReport=1.05 μg ml⁻¹; geometric mean NoRecall=1.18 μg ml⁻¹) groups. CI, confidence interval; UR, unresponsiveness.

	Anaesthetic-induced unresponsiveness				Sleep				Difference in prevalence between sleep and anaesthesia (95% CI)
	Prevalence of report types (n)/number of achieved states (N) (% of recall)
	n of report type/UR1 (%)	n of report type/UR2 (%)	n of report type/UR3 (%)	All UR periods combined∗ (%)	n of report type/N1 (%)	n of report type/N2 (%)	n of report type/N3 (%)	All sleep stages combined (%)
No recall	6/29 (20.7)	4/16 (25.0)	6/31 (19.4)	16/76 (21.1)	4/11 (36.4)	12/33 (36.4)	5/29 (17.2)	21/73 (28.8)	−7.7% (−21.6% – 6.1%)
Dexmedetomidine	2/16 (12.5)	4/14 (28.6)	2/16 (12.5)	8/46 (17.4)
Propofol	4/13 (30.7)	0/2 (0.0)	4/15 (26.7)	8/30 (26.7)
White report	1/29 (3.4)	3/16 (18.7)	3/31 (9.7)	7/76 (9.2)	0/11 (0.0)	4/33 (12.1)	1/29 (3.5)	5/73 (6.8)	2.4% (−6.4% – 11.1%)
Dexmedetomidine	1/16 (6.3)	3/14 (21.4)	3/16 (18.8)	7/46 (15.2)
Propofol	0/13 (0.0)	0/2 (0.0)	0/15 (0.0)	0/30 (0.0)
Content report	22/29 (75.9)	9/16 (56.3)	22/31 (70.9)	53/76 (69.7)	7/11 (63.6)	17/33 (51.5)	23/29 (79.3)	47/73 (64.4)	5.4% (−9.7% – 20.4%)
Dexmedetomidine	13/16 (81.3)	7/14 (50.0)	11/16 (68.8)	31/46 (67.4)
Propofol	9/13 (69.2)	2/2 (100.0)	11/15 (73.3)	22/30 (73.3)